NeuroOne Medical Technologies Corporation reported strong preliminary financial results for its fiscal year ending September 30, 2026. The company achieved approximately $10.5 million in total revenue, marking a 15.6% increase from the previous year. This growth is significant for NeuroOne as it continues to innovate within the surgical and medical instruments industry.
On October 5, 2026, NeuroOne announced its preliminary, unaudited financial results, highlighting a quarterly revenue of approximately $3.8 million for the fourth quarter of fiscal 2026. This represents a robust year-over-year growth of 38.4% compared to $2.7 million in the same quarter of the previous fiscal year.
NeuroOne, trading under the ticker NMTC on the Nasdaq, is a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders. The company has made notable strides in developing innovative products aimed at improving patient outcomes.
According to the SEC filing (accession number 0001213900-26-106677), the company secured a record purchase order worth $4.5 million in September 2026. Approximately $1.0 million of this order was shipped by the end of September, with the remaining $3.6 million expected to ship in the first half of fiscal 2027, contingent upon manufacturing and delivery schedules.
“Momentum continues to build across our business,” said David Rosa, Chief Executive Officer of NeuroOne. “We are happy to report that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. We enter fiscal 2027 from a position of strength supported by $5.4 million in open purchase orders.”
The preliminary results indicate that NeuroOne is well-positioned for future growth, with additional drivers including the commercialization of its trigeminal neuralgia system and international market expansion. The company is also advancing its drug delivery platform, which could further enhance its product offerings.
NeuroOne plans to release complete financial results for the fourth quarter and full fiscal year 2026 in December 2026, coinciding with the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.
The preliminary financial results are subject to final reviews and adjustments, and investors are advised to exercise caution in relying on this information. The company emphasizes that these results may change as they complete their financial closing procedures.
As NeuroOne continues to grow, its performance will be closely watched by industry stakeholders and competitors within the surgical and medical instruments sector.